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Background: Ultraconserved regions (UCR) are genomic segments of more than 200 base pairs that are
evolutionarily conserved among mammalian species. They are thought to have functions as transcriptional
enhancers and regulators of alternative splicing. Recently, it was shown that numerous RNAs are transcribed from
these regions. These UCR-encoded transcripts (ucRNAs) were found to be expressed in a tissue- and disease-specific
manner and may interfere with the function of other RNAs through RNA: RNA interactions. We hypothesized that
ucRNAs have unidentified roles in the pathogenesis of human prostate cancer. In a pilot study, we examined
ucRNA expression profiles in human prostate tumors.
Methods: Using a custom microarray with 962 probesets representing sense and antisense sequences for the 481
human UCRs, we examined ucRNA expression in resected, fresh-frozen human prostate tissues (57 tumors, 7
non-cancerous prostate tissues) and in cultured prostate cancer cells treated with either epigenetic drugs (the
hypomethylating agent, 5-Aza 20deoxycytidine, and the histone deacetylase inhibitor, trichostatin A) or a synthetic
androgen, R1881. Expression of selected ucRNAs was also assessed by qRT-PCR and NanoStringW-based assays.
Because ucRNAs may function as RNAs that target protein-coding genes through direct and inhibitory RNA: RNA
interactions, computational analyses were applied to identify candidate ucRNA:mRNA binding pairs.
Results: We observed altered ucRNA expression in prostate cancer (e.g., uc.106+, uc.477+, uc.363 + A, uc.454 + A)
and found that these ucRNAs were associated with cancer development, Gleason score, and extraprostatic
extension after controlling for false discovery (false discovery rate < 5% for many of the transcripts). We also
identified several ucRNAs that were responsive to treatment with either epigenetic drugs or androgen (R1881). For
example, experiments with LNCaP human prostate cancer cells showed that uc.287+ is induced by R1881 (P < 0.05)
whereas uc.283 + A was up-regulated following treatment with combined 5-Aza 20deoxycytidine and trichostatin A
(P < 0.05). Additional computational analyses predicted RNA loop-loop interactions of 302 different sense and
antisense ucRNAs with 1058 different mRNAs, inferring possible functions of ucRNAs via direct interactions with
mRNAs.
Conclusions: This first study of ucRNA expression in human prostate cancer indicates an altered transcript
expression in the disease.
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Table 1 Clinical characteristics of the prostate cancer
patients in the study
All patients
(n = 57)
Age at prostatectomy (years) [median (range)] 61 (46 – 73)
Largest individual tumor nodule (grams) [median (range)] 1.6 (0.2 – 3.0)
Pathological stage N (%)
2 28 (49)
3 – 4 29 (51)
Gleason grade sum score
< 7 13 (23)
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An ultraconserved region (UCR) is a genomic sequence
with 100% conservation between human, rat, and mouse
genomes. At more than 200 base pairs in length, 481 of
these sequences have been annotated and were found to
be dispersed within intragenic and intergenic regions of
the human genome [1]. Many of the UCRs can be classi-
fied as nonexonic, with the others being either exonic or
possibly exonic. The extreme conservation of these
regions indicate that genetic variations in UCRs are
under a negative selection that is much stronger than it
is for protein coding genes [2]. Given their extreme con-
servation for the last 400 million years, it has been
postulated that these regions must have biological
functions essential to mammalian cells. However, the
possible functions of UCRs have remained largely enig-
matic since their discovery, with some exceptions. For
example, a few ultraconserved regions have been func-
tionally implicated in transcriptional enhancement, alter-
native splicing, or nonsense mediated decay (RNA
surveillance) mechanisms [3-5].
Recently UCRs were identified as the origin of novel
transcripts [6]. Many of them appear to be non-coding
RNAs. Their roles are largely unknown. However, they
may exert their function as non-coding RNAs that regu-
late other RNAs through RNA: RNA interactions [6] or
may have the regulatory roles described for long
intergenic non-coding RNAs (lincRNAs), which form
complexes with proteins and participate in chromatin
regulation [7]. UCRs are frequently located at fragile
sites and genomic regions involved in cancer develop-
ment [6]. Few additional studies have profiled UCR-
derived transcripts and they showed that transcripts
from these regions are distinctively expressed in human
cancer tissues [8]. Similar to known cancer-related
genes, some ucRNAs have been found to undergo CpG
island hypermethylation-associated silencing [9]. How-
ever, only very few of them have been described func-
tionally in cell culture models. For example, uc.73 was
found to influence apoptosis in colon cancer cells [6]
and uc.338 to inhibit the growth of hepatocellular car-
cinoma cells [10]. Together these studies indicate a candi-
date oncogenic function of ucRNAs in the pathogenesis of
cancer.
In the present study, we took an exploratory approach
that was aimed to establish a gene expression profile for
UCR-encoded transcripts in human prostate cancer. To
search for the possible functions of ucRNAs as RNAs
that target protein-coding genes through inhibitory
RNA: RNA interactions, RNA loop-loop interactions
were computationally modeled to discover ucRNA:
mRNA binding pairs. We also tested whether androgen
exposure or epigenetic drug therapy may affect ucRNA
transcript expression. Lastly, we correlated ucRNAexpression with global mRNA and microRNA (miR) ex-
pression to examine relationships between them that
may yield new insight into the function of ucRNAs.
These studies showed that ucRNAs are aberrantly
expressed in prostate cancer and their expression can be
responsive to androgen and epigenetic drugs.Results
ucRNA expression profiles in prostate tumors
The expression of 962 candidate transcripts (ucRNAs)
encoded by the 481 known UCRs (sense and antisense
transcripts: 962) was evaluated with a custom microarray
that was used previously to examine ucRNA expression
profiles in human leukemia and in colon and
hepatocellular cancer [6,9,10]. We analyzed 57 tumors
and 7 non-cancerous prostate tissues. The characteristics
of the cancer patients are shown in Table 1. Applying
Significance Analysis of Microarrays for class compari-
son [11], numerous ucRNAs were found to be differen-
tially expressed after controlling for false discovery [false
discovery rate (FDR) in tables] between tumor and non-
cancerous tissue (see Additional file 1: Table S1 for top-
ranked ucRNAs), between tumors with high and low
Gleason grade (≥ 7 versus ≤ 6) (Additional file 2: Table
S2), and between tumors that showed an extraprostatic
extension of the disease (EPE) and those that did not
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were significantly differently expressed at a stringent
FDR < 5%. Similar numbers of transcripts were up- and
down-regulated in the tumor versus non-tumor contrast,
with the relative change not exceeding the 3-fold range.
This and other contrasts are captured in Figure 1A that
summarizes the differentially expressed ucRNAs for
seven contrasts using a more relaxed FDR < 30%. ToFigure 1 Global expression patterns of ucRNAs in human prostate ca
of ucRNAs found to be altered in human prostate cancer for the various class
disease and SVI = seminal vesicle invasion. (B) Most significantly altered ucRNA
patients. The P < 0.001 (all FDR < 5%) significance level defines an altered tran
high (≥7) vs. low (≤6) Gleason sum score; pT3 vs. pT2 (stage); EPE yes vs. no; S
versus≥ age 61 (age at prostatectomy).further emphasize the most significantly altered
ucRNAs, we applied a stringent P < 0.001 (FDR < 5%)
cutoff to all class comparisons (Figures 1B and 1C),
showing that both sense and antisense transcripts (anti-
sense: +A) were detected among these differently
expressed transcripts. Among these, only few ucRNAs
were differently expressed in more than one contrast.
For example, uc.106+ was up-regulated in tumors (1.8-ncer. (A) The summary chart shows percent and number (in parenthesis)
comparisons at the indicated cutoff. EPE = extraprostatic extension of the
s in tumor and (C) by clinical characteristics of the prostate cancer
script in (B) and (C). Class comparisons in (A) and (C): Tumor vs. normal;
VI yes vs. no; African-American vs. European-American (race); ≤ age 60
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regulated by 30% to 40% in tumors with high Gleason
grade (vs. low grade; P = 0.009) and EPE (vs. without EPE;
P < 0.001). At a P ≤ 0.01 cutoff for differently expressed
genes, uc.34+ and uc.346+ were both down-regulated in
high Gleason grade disease and also high stage disease.
Because a high Gleason score frequently coincides
with high stage disease and presence of EPE, the data
suggest that these ucRNAs are generally down-
regulated with disease progression. The expression of
selected ucRNAs was confirmed with NanoString
technology, as shown in Figure 2A for three of the
most differently expressed UCR-encoded transcripts.
The Nanostring nCounter gene expression system
captures and counts individual RNA transcripts and
has been described in details [12]. Exploratory Predic-
tion Analysis of Microarrays identified a 60 ucRNA
probeset signature (Additional file 4: Figure S1) that
could robustly separate non-tumor (class error rate = 0)
from tumor tissue (class error rate = 5%) with 3 out ofFigure 2 ucRNA expression in prostate tumors and regulation of ucRN
R1881, using NanoString nCounter-based quantification. (A) Up-regula
primary prostate tumors versus the adjacent non-cancerous tissues. Express
described in the methods. The uc.363 + A transcript was found to be most
stage 2 and stage 3 tumors was significantly different (consistent with the
LNCaP cells treated with epigenetic drugs. Expression of uc.283 + A was sig
with one-way ANOVA and Tukey’s posthoc test), with a significant trend fro
(C) Nanostring-based analysis of uc.287+ and uc.283 + A expression in LNC
performed with 10 nM R1881. Shown are the expression changes from unt
experiment; P < 0.05; paired t-test).57 tumors being misclassified, further highlighting the
differences between cancerous and non-cancerous
tissue.
Correlation between ucRNA and host gene expression
Because a subset of the 481 UCRs overlaps with the cod-
ing region for mRNAs, we wanted to characterize the re-
lationship between the expression of ucRNAs and UCR-
encoded mRNAs. Using available Affymetrix GeneChip
mRNA expression data for all tumor tissues, we
performed a correlation analysis between the expression
of those ucRNAs, whose expression was altered in pros-
tate cancer, and corresponding UCR-encoded mRNAs.
This analysis revealed that the expression of the existing
ucRNA-mRNA pairs (n = 146) did not correlate signifi-
cantly with one another, as shown in Figure 3, by the
normal (or Gaussian) distribution with a bell-shaped
probability density function centered around a correl-
ation coefficient of 0. Taken together, our findings indi-
cate that ucRNA expression is principally independentAs by epigenetic drugs and the androgen receptor ligand,
tion of uc.363 + A and uc.477 and down-regulation of uc.454 + A in
ion was measured using the NanoString nCounter system, as
notably up-regulated in stage 3 tumors and expression between
array data). (B) Nanostring-based analysis of uc.283 + A expression in
nificantly up-regulated after treatment with 5-AzaC and TSA (P < 0.05
m untreated to mono treatment to combination treatment (P < 0.05).
aP cells treated with R1881. Three independent experiments were
reated to treated for the experiments (mean of n = 3 per individual
Figure 3 Lack of association between ucRNA expression and the expression of the respective “host” mRNAs in prostate tumors. Shown
is the distribution curve of the Pearson correlation coefficients between tumor-altered ucRNAs and the corresponding UCR-encoded mRNAs. The
correlation coefficient for the ucRNA-mRNA pairs (n = 146) are clustered within the −0.2 to 0.2 range, independent whether pairs are sense (blue)
or antisense (red) transcribed. UCR-encoded mRNAs are defined as mRNA transcripts with a coding region that at least partially overlaps with the
UCR locus. Tumor-altered ucRNAs were defined as being differently expressed between tumor and adjacent non-cancerous tissue at the P ≤ 0.01
significance level.
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human prostate. This is in contrast to the significant
positive correlation seen between miRs and miR host
genes, where miRs tend to be transcribed in parallel with
their host mRNA transcripts [13].
Transcription of UCRs is influenced by epigenetic
mechanisms
To identify epigenetically regulated ucRNAs, we profiled
LNCaP cells that were treated with the DNA
hypomethylating agent, 5-azacytidine (5-AzaC), the histone
deacetylase inhibitor, trichostatin A (TSA), or the combin-
ation of the two. 5-AzaC can induce the expression of
genes that are repressed by DNA hypermethylation [14,15].
Histone deactylase inhibition alters the acetylation status in
a number of substrates, including histones and transcrip-
tion factors, and has been shown to affect the expression of
mRNAs and miRs [16]. LNCaP cells were treated with 5-
AzaC and/or TSA for 36 hrs. Total RNA was collectedfrom these cells and processed as described under methods
and changes in global ucRNA expression were examined
by microarray analysis. Using the OSU-CCC 4.0 array, we
identified six ucRNAs that were consistently up-regulated
in the 3 treatment groups (5-AzaC only, TSA only, and the
combination of both), indicating that these UCRs are
epigenetically silenced in prostate cancer (Table 2). Among
them was uc.283 +A, an antisense transcript encoded by
the intergenic UCR283, which was previously found to be
silenced by promoter CpG hypermethylation in human
colon cancer cells [9]. We confirmed with NanoString tech-
nology that uc.283 + A was up-regulated in 5-AzaC- and
TSA-treated LNCaP cells. This analysis indicated the most
significant up-regulation of uc.283 +A in cells treated with
combined 5-AzaC and TSA (Figure 2B).
Androgen-responsive UCRs
To assess putative androgen-responsive UCRs, we
surveyed the global expression of ucRNAs in androgen-
Table 2 ucRNA expression changes in LNCaP cells in response to treatment with epigenetic drugs
Fold Change*,†
ucRNA 5-AzaC TSA 5-AzaC + TSA Type‡, host gene, host strand Overlap with mRNA Antisense to mRNA
uc.308 + A 3.02 4.66 4.03 n, BTRC, sense Yes Yes
uc.434 + A 2.25 3.84 3.59 n, SKOR2, sense Yes
uc.241 + A 2.03 2.31 3.12 n, no gene No
uc.283 + A 1.90 2.17 2.39 n, no gene No
uc.285+ 1.82 2.14 2.37 e, CCAR1, sense Yes
uc.85+ 1.63 2.03 1.96 n, no gene No
* Fold change: reference are the untreated cells (solvent only); †Cutoff for inclusion: P value (t-test) < 0.01 treatment versus control; ‡ Type is based on UCSC
human genome data, UCSC version hg19, NCBI build 37 coordinates, where, n = nonexonic and e = exonic.
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stimulation with the androgen receptor ligand and agon-
ist, R1881. We preformed the same experiment in
androgen-insensitive DU145 cells to have a negative
control for our system. This experiment identified a
number of ucRNAs that were R1881-responsive in the
LNCaP cells (Table 3). Treatment of the androgen-
insensitive DU145 cells with R1881 did not yield any sig-
nificant changes in ucRNA expression, indicating that
the effect of R1881 in LNCaPs is androgen receptor
pathway-specific. The group of altered ucRNAs
contained both up- and down-regulated transcripts (e.g.,
uc.287+ and uc.283 + A), consistent with mRNA profil-
ing data showing that R1881 induces and represses
protein-coding RNAs in a 24 hr stimulation period [17].
The intergenic uc.287+ was found to be the most con-
sistently up-regulated transcript, which was also
confirmed in an additional experiment with NanoString-
based expression analysis (Figure 2C). We further
examined the androgen-responsive ucRNA loci for the
presence of candidate androgen receptor binding sites. ThisTable 3 ucRNA expression changes in LNCaP cells after treatm
ucRNA Fold Change* FDR (%) P value† Type‡, host
uc.287+ 1.83 7.8 0.034 p, no gene
uc.445 + A 1.44 28.8 0.042 n, no gene
uc.134+ 1.39 28.8 0.029 n, RSRC1
uc.240+ 1.37 28.8 0.019 n, no gene
uc.249 + A 0.80 13.7 0.026 n, no gene
uc.349+ 0.78 13.1 0.021 n, DACH1, a
uc.204+ 0.76 9.7 0.025 n, no gene
uc.135+ 0.65 1.6 0.01 e, MECOM, a
uc.31+ 0.61 1.6 0.025 p, no gene
uc.410 + A 0.58 0.0 0.022 n, no gene
uc.344+ 0.57 0.0 0.037 e, HOXC5, se
uc.283 + A 0.52 0.0 0.032 n, no gene
uc.283+ 0.26 0.0 0.008 n, no gene
* Fold change: reference are the untreated cells (solvent only); †Cutoff for inclusion
data, UCSC version hg19, NCBI build 37 coordinates, where n = nonexonic, e = exonanalysis found that several loci, including the UCR encoding
uc.287+, contain putative binding sites within 1000 base
pairs up- or down-stream of the UCR (Additional file 5:
Table S4), indicating that uc.287+ is a candidate direct tar-
get of the androgen receptor signaling pathway.
Prediction of RNA loop-loop interactions to identify
mRNAs and pathways that are candidate targets of
ucRNAs
A previous report indicated that UCR-encoded
transcripts may exert their function as non-coding RNAs
that regulate other RNAs through RNA: RNA
interactions [6]. However, little is known about these
interactions although their description can provide clues
for mechanisms and functional analysis of otherwise
uncharacterized ucRNAs with an altered expression in
diseases like prostate cancer. To explore this possible
function of UCR-encoded transcripts, we modeled direct
ucRNA:mRNA interactions based on sequence comple-
mentarity and predicted RNA loop-loop interactions as
dynamic functional motifs. This exploratory approachent with R1881














: P value (t-test) < 0.05 for all ucRNAs; ‡ Type is based on UCSC human genome
ic, and p = possibly exonic.
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pairs representing 302 different sense and antisense
ucRNAs and 1058 different mRNAs (Additional file 6:
Table S5), using a folding energy threshold cutoff at
−10 kcal/mol. To infer possible functions of ucRNAs via
interactions with mRNAs, we queried all mRNAs
predicted to form loop-loop interactions with ucRNAs for
an enrichment pattern in Gene Ontology (GO)-defined
biological processes and KEGG-defined pathways. This
analysis revealed a ucRNA target enrichment among
mRNAs for GO processes related to ion binding (P = 9.4 ×
10-7, GO:0043167) and KEGG pathways related to calcium
signaling (P = 8.5 × 10-3). We also queried specific
ucRNAs and found, for example, that uc.454 + A, which
was the most down-regulated ucRNA in prostate tumors,
was predicted to directly interact with Ras signaling
pathway-related transcripts, like RIN2 and RAB37.
Correlation between tissue ucRNAs and expression of
mRNAs and miRs
Because ucRNAs may influence the expression level and
function of other RNAs, we examined available tumor
mRNA and miR expression data (~ 13,000 mRNAs, 238
mature and 143 precursor miRs) to assess whether ucRNA
expression is associated with particular cancer-related
processes in these tumors as indicated by the mRNA ex-
pression profiles, or with the expression of cancer-related
miRs. The correlation analysis was performed for selected
ucRNAs (uc.106+, uc106 +A, uc.248+, uc.454 +A, uc.346+,
uc.363 +A, uc.477+, and uc.477 +A). This analysis revealed
a prominent inverse correlation between uc.106 +A expres-
sion and the expression of many interferon pathway genes
such as IRF7, ISG15, ISG20, OAS1-3, and PTPN22 in pros-
tate tumors (Additional file 7: Table S6). On the other
hand, uc.346 transcript levels correlated with global
miR expression more so than transcript levels of the
other ucRNAs and showed a distinct inverse association
with several miRs including miR-143 (−.77 to -.85 across
probesets; P < 10-10), miR-27 (−.74 to -.75; P < 10-9),
miR-21 (−.69 to -.75; P < 10-8), and miR-16 (−.68 to -
.74; P < 10-7) expression levels and a positive associ-
ation with miR-373 (.84 to .88; P < 10-13) and miR-9
(.78 to .85; P < 10-10) in the prostate tumors. Our ana-
lyses also suggested that sense and antisense transcribed
ucRNAs act independently. Accordingly, we did not find
that mRNA and miR expression profiles, which were sig-
nificantly correlated with sense strand UCR expression,
were also correlated with antisense strand expression from
this location, neither negatively or positively.
A gene expression signature induced by knockdown of
uc.106+ in LNCaP cells
The ucRNA expression profiles of prostate tumors
indicated that UCR106 may encode for cancer-relatedtranscripts. To gain insight into the possible functional
role of RNAs derived from UCR106, LNCaP cells were
transfected with a siRNA designed to target the sense
UCR106 transcript, uc.106+, which was up-regulated
with tumor development but was down-regulated in
cancer progression (high Gleason score tumors and
tumors with EPE). Knockdown of endogenous uc.106+
was confirmed by strand specific qRT-PCR (Figure 4A).
To evaluate whether uc.106+ knockdown may affect cell
function, global expression analysis was then carried out
24 hr post transfection of LNCaP cells using Affymetrix
GeneChips. Numerous genes were found to be up- and
down-regulated in the siRNA-transfected cells when
compared with cells transfected with scrambled siRNA
(control). These genes clustered in distinct pathways
related to proliferation and cell movement, and also can-
cer and immune response (Figure 4B). While prelimin-
ary, the experiment indicates that UCR106-encoded
transcripts may affect cellular transcription pattern in
prostate cancer cells, consistent with the proposed inter-
action between ucRNAs and other RNAs.
Discussion
Key functions of non-coding RNAs in human cancer
have recently been described and several classes of non-
coding RNAs (e.g., miRs, ucRNAs, lincRNAs, snoRNAs)
are now known whose expression is dysregulated in the
disease because of existing oncogenic stimuli, genome
amplifications and deletions, mutations, and epigenetic
silencing [18,19]. Here, we examined the expression of
transcripts encoded by 481 UCRs in prostate cancer,
defined as ucRNAs, and found that ucRNAs can be
detected in the cancerous human prostate and show a
disease-specific expression pattern. When we compared
the expression of ucRNAs in prostate cancer with other
human cancer types, e.g., leukemia, colon cancer, liver
cancer, and neuroblastoma [6,10,20,21], we did not find
a common ucRNA expression signature among them.
Thus, ucRNA expression is rather tissue-specific and
cancer type-specific, which is reminiscent of miR expres-
sion patterns in solid human tumors [22,23]. However, it
appears that even fewer ucRNAs than miRs are com-
monly dysregulated across tumor types, as we could not
identify any commonly dysregulated ucRNAs between
our study and other ucRNA studies. We also observed
that only very few UCRs encoded for transcripts that
were associated with both disease onset and progression.
Among them were UCR106 and UCR346 that were
found to encode for sense and antisense transcripts
(uc.106+, uc.106 + A, uc.346+, uc.346 + A) and whose
expression was dysregulated in primary tumors and with
disease stage and Gleason grade. Previous studies identi-
fied robust miR signatures only for the tumor versus
non-cancerous tissue contrast, but did not find those
Figure 4 Knockdown of uc.106+ alters expression of cell proliferation, motility, and inflammatory genes in LNCaP cells. (A) Knockdown
of uc.106+ in LNCaP cells at 24 hr after transfection with siRNA targeting uc.106+ (or scrambled siRNA as control). * P < 0.05 (versus control).
(B) Pathway analysis with the 200 top-ranked genes which were significantly up- or down-regulated after siRNA transfection across 3 independent
experiments. The analysis shows significant clustering of these genes in several biological processes including cell proliferation and movement,
and inflammation.
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differences in prostate cancer [24-26]. Our study of
ucRNAs concurs with these findings.
The underlying mechanisms that cause cancer-specific
ucRNA expression are largely unknown but may include
mutational events and epigenetic regulation. Some UCRs
are regulated by epigenetic silencing, as was shown re-
cently [9], which is consistent with the well established
regulation of other non-coding RNAs, like miRs, by this
mechanism [27]. Our study identified 6 ucRNAs whose
expression significantly increased after treatment of
LNCaP cells with the two epigenetic drugs, 5-AzaC and
TSA. Of those, uc.283 + A was up-regulated by these
drugs in both our study and the study by Lujambio and
coworkers, who also showed that the uc.283 + A locus is
silenced by CpG hypermethylation in a human colon
cancer cell line [9]. We did not examine the uc.283 + A
locus in more detail but the consistent finding in the
two studies (present study and [9]) identifies uc.283 + A
as an epigenetically regulated transcript. UCR283 is
located in an intergenic genomic region and does not
overlap with the coding region for any mRNA. While
epigenetic regulation of UCR283 could be observed in
the LNCaP cells, we did not find that transcription from
UCR283 was significantly altered in human prostate
tumors but noticed that two of the six epigenetically
regulated ucRNAs, uc.241 + A and uc.285+, were down-
regulated in these tumors when compared with adjacent
non-cancerous tissue. Thus, future investigations are
needed to define the importance of ucRNA silencing in
human prostate cancer biology.
Another important mechanism of gene regulation in
prostate biology and prostate cancer progression is the
activation of the androgen receptor signaling pathway
[28]. It has been shown that non-coding RNAs like miRsare regulated by androgen signaling [25,29-31]. We
examined the effect of the androgen receptor agonist,
R1881, in androgen-sensitive LNCaP cells and surveyed
global expression changes by ucRNAs. Our experiment
was restricted to one dose of R1881 and future
experiments would have to investigate R1881 effects on
UCR transcription using a broader dose range and a lar-
ger panel of cell lines. Nevertheless, this exploratory ana-
lysis identified several ucRNAs that were induced by
R1881, though only the up-regulation of uc.287+ was
robust. In contrast, multiple ucRNAs were found to be
significantly down-regulated in response to R1881.
Among them was uc.283+, which was the most signifi-
cantly repressed transcript. We did not find that any of
these androgen-responsive ucRNAs are differently
expressed in primary human prostate tumors, when
compared with non-cancerous prostate tissue, or were
associated with Gleason grade or disease stage, nor did
we find that these ucRNAs were, with the exception of
uc.135+, described in other ucRNA studies [6]. Thus,
they do not appear to be cancer-associated ucRNAs in
the primary disease. Nevertheless, it remains a possibility
that these transcripts are differently expressed between
castration-resistant and castration-sensitive prostate
tumors, which we could not investigate.
Like with most non-coding RNAs other than miRs,
our current knowledge with respect to the function of
ucRNAs is very limited. Only a few full length ucRNA
transcripts have been described. Because of these
limitations, we used siRNA to knockdown uc.106+ ex-
pression and also decided to apply computational ana-
lyses to predict RNA-RNA interactions between ucRNAs
and mRNAs based on the available coding sequence
from the 481 described UCR loci, and to link these
interactions to possible functions of the ucRNAs. In
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mRNA, and miR expression data to discover functional
associations between selected ucRNAs and both miRs
and mRNAs. These are exploratory tools that can yield
new insight into ucRNAs in the absence of other
supporting information in this largely unexplored re-
search field. Down-regulation of uc.106+ generated a
robust gene expression profile in LNCaP cells, indicating
that uc.106+ is a functional transcript and suggesting
that UCR106 encoded transcripts may have a function in
prostate cancer. Future research is needed to clone can-
didate non-coding transcripts encoded by UCR106 to
allow functional analysis of them in phenotypic assays.
Other analyses also revealed a significant enrichment for
predicted ucRNA:mRNA interactions in processes
related to ion binding and calcium signaling, suggesting
that ucRNAs may target calcium signaling processes.
Our approach also showed that expression of uc.106 + A
(antisense transcript of UCR106) in prostate tumors may
influence the interferon signaling pathway by either a
direct or indirect mechanism in prostate tumors, as
was indicated from the inverse relationship between
uc.106 + A expression and expression of multiple inter-
feron pathway genes. Notable, UCR106 also encodes a
DNA damage-regulated gene and ATPase, termed OLA1
or Obg-like ATPase, which is a putative GTP-binding pro-
tein involved in mitochondrial function and regulation of
the oxidative stress response [32,33]. UCR106 is located in
an intronic region of this gene and we did not find a cor-
relation between OLA1 expression and the expression of
either uc.106+ or uc.106 + A. While these are only few
examples of candidate functions for ucRNAs in prostate
cancer, our exploratory work shows that these approaches
can be useful in potentially uncovering the biology of
ucRNAs in cancer biology.
Conclusions
This first study of ucRNA expression in the cancerous
human prostate shows a disease-specific expression pat-
tern for this class of transcripts. Future studies are
needed to further define the functional implication of




Fifty-seven fresh-frozen primary prostate tumors, 7 non-
cancerous prostate tissues from prostatectomy (not
paired to the tumors in the study), and additional patient
information were received from the National Cancer
Institute (NCI) Cooperative Prostate Cancer Tissue
Resource (CPCTR). All tissues were collected between
2002 and 2004 through CPCTR. Non-tumor tissues were
collected from patients whose prostate was resectedbecause of a prostate cancer diagnosis. These tissues did
not contain tumor per assessment by a pathologist.
Tumors were surgically resected adenocarcinomas from
patients who had not received any therapy prior to pros-
tatectomy. Their characteristics are described in Table 1.
These tumors were macrodissected by a CPCTR path-
ologist who also confirmed that the frozen tissue speci-
men is tumor. Tissue collection and its use was
reviewed and approved by the institutional review
boards of the participating institutions in the CPCTR
and the NIH Office of Human Subjects Research. Writ-
ten informed consent was obtained from all donors.
RNA isolation
Total RNA was isolated using TRIZOL reagent
according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). RNA integrity for each sample was
confirmed with the Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA).
Expression microarrays
The Ohio State University Comprehensive Cancer Cen-
ter (OSU-CCC) Version 2.0 custom microarray was used
for ucRNA and miR expression profiling and the
Affymetrix GeneChip HG-U133A 2.0 microarray for
mRNA expression profiling, following previously
published protocols [6,34,35]. The OSU-CCC microarray
was developed with a total of 962 probesets representing
sense and antisense sequences for the 481 human UCR as
in http://users.soe.ucsc.edu/~jill/ultra.html. An updated
UCR annotation (location, type, transcripts) based on
UCSC human genome data, UCSC version hg19, NCBI
build 37 coordinates, can be found for selected ucRNAs in
Additional file 8: Table S7. For each UCR two 40-mer
probes were designed, one corresponding to the sense
genomic sequence (named “+”) and the other to the com-
plementary sequence (named “+A”). Each oligo was
printed in duplicate in two different slide locations, and
therefore quadruplicate numerical values were available
for analysis. Several thousand (3484) blank spots were
used for background subtraction. Labeling and
hybridization of ucRNA transcripts were performed as
described previously [34]. Briefly, 5 μg of RNA from each
tissue sample was labeled with biotin by reverse tran-
scription using random octomers. Hybridization was
carried out onto the OSU-CCC Version 2.0 microarray,
which contained the 962 UCR probes, 238 probes for
mature miRs, and 143 probes for precursor miRs. More
information about this custom microarray can be found
under the ArrayExpress accession number: A-MEXP
-258. Hybridization signals were detected by biotin
binding of a Streptavidin-Alexa647 conjugate (one-
color signal) using a GenePix 4000B scanner (Axon
Instruments). Images were quantified using the
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hybridization of mRNAs from the same tissues were
performed according to Affymetrix standard protocols
(Santa Clara, CA). Briefly, 5 μg of total RNA was re-
verse transcribed with an oligo (dT) primer that has a
T7 RNA polymerase promoter at the 50 end. Second-
strand synthesis was followed by cRNA production with
incorporation of biotinylated ribonucleotides using the
BioArray High Yield RNA Transcript Labeling Kit T3
from Enzo Life Sciences (Farmingdale, NY). The labeled
cRNA was fragmented and hybridized to Affymetrix
GeneChip HG-U133A 2.0 arrays. This array contains
22,283 probe sets that represent approximately 13,000
human protein-coding genes. Hybridization signals were
visualized with phycoerythrin-conjugated streptavidin
(Invitrogen) and scanned using a GeneChip Scanner 3000
7 G (Affymetrix). In accordance with Minimum Informa-
tion About a Microarray Experiment (MIAME) guidelines,
we deposited the CEL files for the microarray data and
additional patient information into the GEO repository
(http://www.ncbi.nlm.nih.gov/geo). Normalized and raw
data files for the ucRNA, miR, and mRNA profiling data
have been uploaded to GEO (http://www.ncbi.nlm.nih.
gov/geo) under GEO accession GSE7055, as described
previously [35]. The OSU-CCC 4.0 microRNA array was
used for profiling of ucRNAs in prostate cancer cells
treated with R1881 or epigenetic drugs. Normalized
and raw expression data from these cell-based
experiments were deposited into GEO under the acces-
sion number GSE31620. GEO also describes the OSU-
CCC 4.0 platform under the accession number
GPL14184.
Data normalization and statistical analysis of microarray
data
Median-centric normalization was used for the OSU-
CCC 2.0 custom microarray. Affymetrix arrays were
normalized using the robust multichip analysis (RMA)
procedure [36]. To generate lists of differently expressed
transcripts (ucRNAs, miRs, mRNAs) between classes
(e.g. tumors versus non-cancerous tissue), the resulting
dataset was subjected to the Significance Analysis of
Microarrays [11]. A description of SAM can be found at
http://www-stat.stanford.edu/~tibs/SAM. We generated
gene lists based on both P values from two-sided t-tests
and intended false discovery rates (FDRs) and report
both for our findings of differently expressed genes as
fold change compared to the reference with P value and
FDR. The FDR calculation followed the method
described by Storey and Tibshirani [37]. False discovery
control by calculating FDRs is a statistical method used
in multiple hypotheses testing to correct for multiple
comparisons, especially relevant for high-throughput
data such as expression microarrays where changes inmany genes are measured at the same time. Although
the range of a FDR acceptable for a particular study
depends on the actual dataset, in general, a FDR (or q-
value) < 5% for a differently expressed transcript is usu-
ally used as cutoff for a statistical significant finding but
FDRs at 5-10% or even higher can be meaningful. This
has been described in more details in the references we
cited and the URL for the SAM method. We used Pre-
diction Analysis of Microarrays [38] to classify tissues
into tumor and non-tumor tissue based on their ucRNA
expression pattern. Pathway analysis was performed with
Ingenuity (IngenuityW Systems, www.ingenuity.com). For
the analysis of the cell-based experiments with OSU-
CCC 4.0 arrays, the raw GPR data files were imported
into BRB array tools. Median normalization was carried
out and spots were filtered for low intensities and mini-
mum fold-change. Probe sets with 50% missing or
filtered data were excluded. Class comparisons between
treatments were carried out using the randomized block
univariate t-test across all samples.
NanoString nCounter evaluation of ucRNA expression
The nCounter gene expression system utilizes a novel
digital technology that is based on a direct measurement
of gene expression (http://www.nanostring.com). The
technology uses molecular barcodes and single molecule
imaging to detect and count transcripts. It has been
described in details [12]. Nanostring nCounter codesets
for ucRNAs were designed and produced based on the
published sequences for the corresponding UCRs and
are listed in Additional file 9: Table S8. Expression ana-
lysis was performed according to the written protocol
provided by NanoString Technologies (Seattle, WA).
Briefly, a 5 μl aliquot containing 100 ng of denatured
total RNA was added to 20 μl of master mix consisting
of equal amounts of Reporter CodeSet solution and
hybridization buffer. Five μl of Capture ProbeSet were
added to the mix the hybridization was performed over-
night at 65C. Post-hybridization processing was performed
at the NCI/CCR DNA Sequencing and Digital Gene Ex-
pression Core Facility. Raw counts were normalized to in-
ternal mRNA levels of the GUSB gene.
Treatment of prostate cancer cells with R1881
For sex hormone depletion, DU145 and LNCaP human
prostate cancer cells were placed in phenol red-free
RPMI 1640 with 5% charcoal-treated FBS for 48 hours.
Cells were then treated with either 10 nM R1881
(methyltrienolone; PerkinElmer Life Sciences, Waltham,
MA) or solvent (ethanol). After 24 hrs, cells were
harvested and total RNA was isolated. This experiment
was repeated five times and the RNA was processed for
microarray-based expression analysis as described under
“Expression microarrays”. The same treatment protocol
Hudson et al. Molecular Cancer 2013, 12:13 Page 11 of 13
http://www.molecular-cancer.com/content/12/1/13was used to validate uc.287+ up-regulation with the
Nanostring nCounter gene expression system. A search
for putative androgen receptor binding sites in or nearby
selected UCR locations was performed with the
Genomatix software (München, Germany).
Treatment of prostate cancer cells with 5-Aza
20deoxycytidine (5-AzaC) and Trichostatin A (TSA)
LNCaP cells were treated with 5-azacytidine (5-AzaC)
and/or trichostatin A (TSA) (Sigma, Saint Louis, MO,
USA) following similar schemes reported by others [39].
Briefly, cells were plated at 1x106 cells per 10 cm2 for
48 hrs and then treated with dimethylsulfoxide (DMSO)
as a control and 5-AzaC (5 mM), and/or TSA (0.3 mM).
For combined treatments, TSA was added after 12 hrs of
pre-treatment with 5-AzaC or control. After 36 hrs, cells
were harvested for RNA extraction. N = 4 for 5-AzaC +
TSA, n = 5 for all others.
Knockdown of uc.106+ with siRNA and gene expression
profiling
LNCaP cells were transiently transfected with siRNA
oligos (Qiagen, Valencia, CA) targeting the uc.106+ tran-
script target sequence, ATGGTGTGAAGTATAGGTTAA,
encoded by UCR106 using lipofectamine 2000, as
described by the manufacturer (Invitrogen), or with
scrambled siRNA oligos as negative control (non-targeting
control). Strand-specific quantification of uc.106+
knockdown: Single strand cDNA synthesis was performed
using the ThermoScript RT-PCR system (Invitrogen)
following the manufacturer’s suggested procedures.
Briefly, 1 μg of DNase I (Amp Grade 1 U/μl; Invitrogen)
treated RNA, 10 μM of sense uc.106 region specific
primers (PrimerDesign Ltd., Southampton, UK) along
with U6 TaqManW MicroRNA Assay primers (Applied
Biosystems), and 10 mM dNTP were denatured by incu-
bating at 65C for 5 minutes. Next, a mixture of 5x cDNA
synthesis buffer, 0.1 M DTT, and RNAseOUT was added
and the reaction was incubated at 60 min at 50C. The re-
action was then terminated by heating to 85C for 5 -
minutes and then incubated with RNase H for 37C for
20 minutes. Real-time PCR was performed using standard
protocols on an Applied Biosystem’s 7900HT Sequence
Detection System (SDS) using 2x SYBR green PCR master
mixes (Applied Biosystems) for uc.106+ or Taqman 2x
Universal PCR Master Mix for quantification of the in-
ternal control U6. Cycle number threshold (CT) was
calculated automatically within SDS software and fold
change of gene expression was calculated using the com-
parative CT method. For genome-wide mRNA expression
analysis following uc.106+ knockdown, total RNA was
isolated with the the TRIzol reagent at 24 hr post siRNA
transfection. For arrays, 250 ng of total RNA was ampli-
fied using the Affymetrix GeneChip 3’ IVT Express Kit.After fragmentation, aRNA was hybridized onto
Affymetrix GeneChip HG-U133A 2.0 according to
Affymetrix standard protocols.
Prediction of loop-loop RNA interactions
Putative ucRNA-mRNA interactions were evaluated
based on predicted loop-loop RNA interactions using
the RNAfold program from the Vienna package for the
folding analysis [40] and derived custom scripts for the
analysis of loop-loop interactions, similar to previously
described general procedures to predict these
interactions [41]. The RNAfold software was used to
predict secondary structures for transcribed UCR
sequences and for mRNAs in the REFseq collection.
Loop subsequences of these structures were then
predicted and possible pairs of ucRNA-mRNA
sequences were evaluated for their joint structure and
folding energy. For predicted interactions, the folding
energy threshold was set at greater than −10 kcal/mol
and the number of bonds in the ucRNA-mRNA pair had
to be more than 75% within the evaluated sequence.
Statistical analysis beyond microarrays
We used t-tests (paired and unpaired), ANOVA, and the
Pearson correlation test in our statistical analysis. All
statistical tests were two-sided, and an association was
considered statistically significant with P values < 0.05.
Additional files
Additional file 1: Table S1. Listing the top-ranked ucRNAs differently
expressed between cancerous and non-cancerous human prostate tissue.
Additional file 2: Table S2. Listing the top-ranked ucRNAs associated
with Gleason score.
Additional file 3: Table S3. Listing the ucRNAs associated with
extraprostatic disease extension.
Additional file 4: Figure S1. Summarizing the shrunken centroid
differences (dik) for each of a 60 ucRNA probeset classifier that
differentiated cancer from non-cancerous tissue in the human prostate.
Additional file 5: Table S4. Listing putative androgen-related receptor
binding sites in R1881-responsive ultraconserved regions.
Additional file 6: Table S5. Listing predicted interactions between
ucRNA transcripts (sense and antisense transcribed) and mRNAs.
Additional file 7: Table S6. Summarizing the correlation of ucRNA106
+ A with mRNA expression in human prostate tumors.
Additional file 8: Table S7. That contains the updated annotation of
selected UCR-encoded transcripts based on UCSC version hg19, NCBI
build 37 coordinates.
Additional file 9: Table S8. Containing the target sequences in
selected ucRNAs for the Nanostring probe design.
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